Memantine (Namenda): Uses, Dosing, Side Effects, and How It Compares to Other Cognitive Medications

What Is Memantine and How Does It Work?

Memantine is a low-to-moderate affinity, uncompetitive antagonist at N-methyl-D-aspartate (NMDA) glutamate receptors. It enters open ion channels, blocks pathological calcium influx, and leaves quickly enough during normal synaptic firing that it does not appear to interfere with the signaling needed for learning and memory. This kinetic profile separates it from tightly binding NMDA blockers such as ketamine and phencyclidine, which produce far more disruptive psychoactive effects at comparable receptor occupancy.

The rationale in Alzheimer's disease is that chronically elevated ambient glutamate produces sustained, low-level NMDA receptor activation. That background activity is thought to blur the distinction between active and resting synapses and to contribute to excitotoxic neuronal injury over time. Memantine is intended to dampen this tonic signal without blocking the phasic bursts associated with new memory formation.

The FDA approval rested on a pivotal 28-week trial in patients with moderate-to-severe Alzheimer's disease (Reisberg et al., 2003, N=252), which found a statistically significant advantage for memantine over placebo on the Severe Impairment Battery (SIB) and the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), P<0.001 [1]. The trial is widely cited as showing a modest but real separation from placebo rather than a large effect; readers who need the exact point-level SIB and CIBIC-Plus differences for clinical decision-making should confirm them directly against the published trial report [1] rather than relying on secondary summaries.

Memantine has no cholinesterase-inhibitor activity and does not raise acetylcholine levels. Clinicians who want both mechanisms in one prescription often use Namzaric, the fixed-dose capsule combining memantine XR 28 mg with donepezil 10 mg.

FDA-Approved Indications and Off-Label Prescribing

The only FDA-approved indication for memantine is moderate-to-severe Alzheimer's disease in adults [2]. "Moderate to severe" is operationally associated with a Mini-Mental State Examination (MMSE) score in roughly the 3 to 14 range, though clinical judgment governs individual cases.

Off-label uses that have been studied, with varying strength of evidence:

• Vascular dementia. A Cochrane review identified small, statistically significant but clinically uncertain benefits on cognition and global outcomes.
• Mild cognitive impairment (MCI). Randomized trials, including the MCI-SIM study, have not shown a significant benefit over placebo in patients with higher (less impaired) MMSE scores. American Academy of Neurology practice guidance on MCI does not support memantine as a treatment for this population [10].
• Obsessive-compulsive disorder (OCD) augmentation. Small open-label trials suggest possible benefit as an add-on to serotonin reuptake inhibitors, but no large randomized trial has confirmed this, and it is not an approved use.
• Autism spectrum disorder. Reported results across small studies are mixed, and the FDA has not approved this use.
• ADHD. A small number of case series and pilot trials have examined memantine for inattention symptoms. Reported benefits, where present, have been modest and well below the effect sizes seen with stimulant medications. This is not an FDA-approved use, and no major guideline recommends memantine for ADHD; specific trial-level statistics for this use should be verified against the primary literature before being cited to a patient.

Prescribers should document the rationale and discuss it with the patient or caregiver before starting any off-label use.

Dosing and Titration for Memantine

The standard titration schedule for the immediate-release formulation starts at 5 mg once daily for one week, increases to 5 mg twice daily in week two, to 5 mg and 10 mg (morning and evening) in week three, and reaches the 10 mg twice-daily (20 mg/day total) target in week four [2]. The extended-release capsule (Namenda XR) starts at 7 mg once daily and increases by 7 mg weekly to a 28 mg/day target, intended to approximate the same total daily exposure.

Renal function materially affects dosing. For a creatinine clearance (CrCl) under 30 mL/min, the FDA label specifies a maximum dose of 5 mg twice daily for the IR formulation, or 14 mg/day for XR [2]. No dose adjustment is specified for mild-to-moderate hepatic impairment, and memantine has not been well studied in severe liver disease.

Alkaline urine slows renal elimination of memantine and can raise plasma levels. Conditions or drugs that substantially raise urinary pH, such as carbonic anhydrase inhibitors or heavy use of sodium bicarbonate, warrant closer monitoring.

Clinical Efficacy: What the Trials Show

The Reisberg trial described above remains the cornerstone evidence for the original approval: a statistically significant advantage for memantine over placebo on the SIB and CIBIC-Plus at 28 weeks in moderate-to-severe disease (P<0.001) [1].

A 2019 Cochrane review pooling ten trials in people with moderate to severe Alzheimer's disease (McShane et al., N=2,959) concluded: "Memantine has a small beneficial effect on cognition, behavior, and the ability to perform activities of daily living at 6 months in people with moderate to severe Alzheimer's disease" [3]. The review frames this as a real but modest effect, translating to a small number of points on cognitive scales such as the ADAS-Cog, below the threshold many clinicians consider clearly noticeable day to day, but consistently favoring memantine over placebo across the pooled trials [3].

A separate 24-week trial in mild-to-moderate Alzheimer's disease (Peskind et al., MEM-MD-02, N=433) did not find a statistically significant advantage for memantine over placebo on the primary ADAS-Cog outcome, which is consistent with the label's restriction to moderate-to-severe disease [4].

The DOMINO-AD trial (Howard et al., NEJM, 2012, N=295) followed patients who had reached moderate-to-severe disease after at least three years on donepezil, randomizing them to continue donepezil, add memantine, do both, or stop both. Continuing donepezil, adding memantine, or both produced better outcomes on the Standardized MMSE and the Bristol Activities of Daily Living Scale than stopping both drugs, with the authors describing the combination as offering additive rather than synergistic benefit [5]. The exact point differences reported for SMMSE and Bristol ADL scores in that trial should be checked against the published paper before being quoted precisely, since secondary summaries of this trial vary in how they report the numbers.

Side Effects and Safety Profile

Memantine is generally well tolerated. In pooled trials, adverse events occurring more frequently with memantine than placebo included dizziness (7% vs. 5%), headache (6% vs. 3%), confusion (6% vs. 4%), and constipation (5% vs. 3%) [2].

Because memantine is not a stimulant, it does not raise heart rate or blood pressure, suppress appetite, or disrupt sleep architecture the way amphetamine-based medications can. Patients with cardiac disease or hypertension who cannot tolerate stimulants sometimes find this side-effect profile more manageable.

Serious adverse events are uncommon. Post-marketing reports include isolated cases of Stevens-Johnson syndrome and other severe skin reactions; patients should stop the medication and seek care promptly for any new rash accompanied by systemic symptoms such as fever or mucosal involvement. Seizure threshold may be slightly lowered in theory, though controlled trials have not shown a statistically significant increase in seizure rates.

Drug interactions are limited but real. Amantadine, ketamine, and dextromethorphan act at the same NMDA binding site and are generally not combined with memantine. Drugs or conditions that alkalinize urine may slow memantine clearance and raise plasma levels.

How Memantine Differs From Stimulant Medications

Patients and caregivers sometimes confuse memantine with stimulant medications used for attention or wakefulness, because both categories get discussed under "cognitive medications." The mechanisms and approved populations are unrelated.

Modafinil and armodafinil are wakefulness-promoting agents approved for narcolepsy, shift-work sleep disorder, and residual sleepiness in obstructive sleep apnea. They are Schedule IV controlled substances and are not approved for or studied as Alzheimer's treatments. A review of modafinil's cognitive effects in healthy volunteers found modest benefits during sleep deprivation but smaller and less consistent effects during normal wakefulness [6].

Methylphenidate and amphetamine salts (Adderall and related products) are Schedule II stimulants approved primarily for ADHD and, for some formulations, narcolepsy. The Multimodal Treatment Study of Children with ADHD found that medication management produced significantly greater symptom reduction than behavioral therapy alone [7], and a large network meta-analysis ranked methylphenidate among the most effective ADHD medications in children, with amphetamines generally showing larger effects in adults [8]. Neither drug is approved for Alzheimer's disease. A small trial did find that methylphenidate improved apathy and caregiver-rated global function in Alzheimer's patients, without significantly changing cognitive test scores (Mintzer et al., ADMET 2, N=200) [9], a distinct, narrower use case from memantine's role in the same disease.

None of these stimulants are substitutes for memantine in Alzheimer's disease, and memantine is not a substitute for stimulant therapy in ADHD or narcolepsy.

HealthRX.com Decision Framework: What Actually Changes the Plan With Memantine

Memantine in Combination with Cholinesterase Inhibitors

Combining a cholinesterase inhibitor (donepezil, rivastigmine, or galantamine) with memantine has a straightforward pharmacological rationale: cholinesterase inhibitors raise acetylcholine by slowing its breakdown, while memantine targets glutamate-driven excitotoxicity. The two mechanisms do not overlap and do not share major toxicities.

The DOMINO-AD trial provides the best evidence for this combination in practice. Patients who continued donepezil, added memantine, or did both scored better on the Standardized MMSE and Bristol ADL scale than those who stopped both drugs [5]. As above, treat any specific point-difference figures for this trial as needing direct confirmation against the original NEJM report before they are used in patient-facing claims.

The Namzaric fixed-dose capsule (memantine XR 28 mg / donepezil 10 mg), approved by the FDA in December 2014, simplifies adherence for patients already stable on donepezil 10 mg [2]. For caregivers managing multiple medications for a person with dementia, reducing pill count can matter as much as the pharmacology.

Monitoring and Follow-Up

Clinicians prescribing memantine should check renal function (serum creatinine or a metabolic panel) before starting treatment and periodically thereafter, since renal clearance governs drug levels. Cognitive assessments using the MMSE or Montreal Cognitive Assessment every several months give a structured picture of trajectory, though memantine's effect size means visit-to-visit fluctuation can exceed the drug's average benefit.

Blood pressure monitoring is not specifically required by the memantine label, unlike stimulant medications, but Alzheimer's patients are frequently on antihypertensives and other cardiovascular drugs, so medication reconciliation at each visit still matters.

Discontinuation decisions should be individualized. As disease reaches the very severe stage, the evidence base for continued benefit thins, and the risk-benefit discussion shifts toward minimizing polypharmacy and focusing on comfort and goals of care.

Practical Prescribing Considerations

Memantine is available as a generic, and the price gap versus branded Namenda XR is substantial; generic memantine is typically far less expensive than brand-name extended-release products, and most insurance formularies favor the generic. Readers should confirm current pricing with their pharmacy, since costs shift over time.

The memantine XR capsule can be opened and sprinkled over soft food such as applesauce for patients who cannot swallow capsules, per the FDA label [2]. This can help patients with dysphagia, which is common in moderate-to-severe Alzheimer's disease.

Patients switching from memantine IR 10 mg twice daily to Namenda XR 28 mg once daily can generally make the switch the day after the last IR dose, without re-titration, per the prescribing information [2].

Memantine's renal and skin-reaction precautions aside, it is not flagged the way many other CNS-active drugs are on standard older-adult prescribing safety lists, which is one reason some prescribers view its overall side-effect burden as comparatively manageable in this population; a prescriber should still weigh it against the individual's full medication list and kidney function.